Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT02711007

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy

Sponsor: GUO WEI

Conditions Metastasis Osteosarcoma

Interventions apatinib

Updated 7 times since 2017 Last updated: Apr 19, 2018 Started: Mar 31, 2016 Primary completion: Dec 30, 2017 Completion: Jan 8, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Metastasis and Osteosarcoma and is currently completed. GUO WEI leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
May 2018 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — May 2018 [monthly]

Recruiting PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GUO WEI

Data source: Peking University People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China